Protagonist Therapeutics (PTGX) Depreciation and Depletion (2020 - 2022)

Protagonist Therapeutics has disclosed Depreciation and Depletion across 3 years of filings, most recently posting $254000.0 for Q4 2022.

• Depreciation and Depletion for Q4 2022 came in at $254000.0, up 8.09% year-over-year; the trailing twelve-month figure through Dec 2022 was $1.0 million (up 26.94% YoY), and the FY2025 annual result was $1.2 million, up 37.02% from the prior year.
• Depreciation and Depletion came in at $254000.0 for Q4 2022 at Protagonist Therapeutics, down from $270000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $270000.0 in Q3 2022 to a low of $180000.0 in Q1 2021.
• The 3-year median for Depreciation and Depletion is $235000.0 (2021), against an average of $225888.9.
• Peak annual rise in Depreciation and Depletion reached 40.0% in 2022, while the deepest fall reached 8.09% in 2022.
• Protagonist Therapeutics' Depreciation and Depletion stood at $188000.0 in 2020, then gained by 25.0% to $235000.0 in 2021, then gained by 8.09% to $254000.0 in 2022.
• The last three Depreciation and Depletion figures came in at $254000.0 (Q4 2022), $270000.0 (Q3 2022), and $259000.0 (Q2 2022), per Business Quant data.